Amarin Supported Peer Reviewed Articles EPA Research, Case Studies, Overviews

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients. Vasc Health Risk Manag. 2019;15:533-538.

Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk By Statin Use In U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. Diabetes Care. 2019. [Epub ahead of print]

Nordestgaard BG. Triglycerides, Lesson from Genetics. EMJ Cardiol. 2019;7:57-59.

Bhatt DL. Does High-Dose Fish Oil Reduce Cardiovascular Events Via Triglycerides? EMJ Cardiol. 2019;7:59-60.

Gitt AK. Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS. EMJ Cardiol. 2019;7:61-62.

Toth PP, Philip S, Hull M, Granowitz C. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients. Mayo Clin Proc. 2019;94(9):1670-1680.
https://www.mayoclinicproceedings.org/article/S0025-6196(19)30382-9/fulltext

Toth PP, Philip S, Hull M, Granowitz C. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis. Clin Cardiol. 2019;1–6.

Case BC, Bress A, Kolm P, Philip S, Herrick J, Granowitz C, Toth P, Fan W, Wong N, Hull M, Weintraub S. The Economic Burden of Hypertriglyceridemia Among US Adults With Diabetes or Atherosclerotic Cardiovascular Disease on Statin Therapy. J Clin Lipidol. 2019; epub ahead of print.

Nelson JR, Raskin S. The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. Postgraduate Med. 2019;131:268-277.

Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease. J Am Coll Cardiol. 2019;73:1362-1364.
https://www.ncbi.nlm.nih.gov/pubmed/30819552